Chelsea Vows To Resolve Latest Regulatory Woes With Northera Quickly
This article was originally published in The Pink Sheet Daily
Executive Summary
Technical deficiencies foil the resubmission of Chelsea Therapeutics’ Northera. The company thinks it can resolve the problems quickly and some analysts expect a relatively short delay of one or two months to the user fee date.